Ketamine/temsirolimus

Ketamine/temsirolimus is a combination of ketamine, an NMDA receptor antagonist, and temsirolimus, a mammalian target of rapamycin inhibitor, which is under development for the treatment of major depressive disorder. It is being developed to prolong the antidepressant effects of ketamine and esketamine, by 2 to 3times, from 2 to 7days to 14days in terms of preliminary clinical findings. The combination is being developed by Freedom Biosciences. As of April 2024, it is in phase 2 clinical trials.